

Liuyan Jiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7110028/publications.pdf>

Version: 2024-02-01

52
papers

931
citations

840776

11
h-index

454955

30
g-index

52
all docs

52
docs citations

52
times ranked

1270
citing authors

#	ARTICLE	IF	CITATIONS
1	ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. <i>Blood</i> , 2014, 124, 1473-1480.	1.4	401
2	Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements. <i>American Journal of Surgical Pathology</i> , 2016, 40, 36-43.	3.7	103
3	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	1.4	97
4	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	1.4	55
5	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3 ^{hi} /dimCD4 ⁺ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <i>Modern Pathology</i> , 2016, 29, 1173-1182.	5.5	36
6	Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. <i>Cancer Medicine</i> , 2018, 7, 499-507.	2.8	29
7	Epidemiology of adult acute myeloid leukemia: Impact of exposures on clinical phenotypes and outcomes after therapy. <i>Cancer Epidemiology</i> , 2015, 39, 1084-1092.	1.9	27
8	Extranodal Rosai-Dorfman Disease of the Bone Treated with Surgery and Radiotherapy. <i>Rare Tumors</i> , 2014, 6, 132-134.	0.6	23
9	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2018, 183, 196-211.	2.5	16
10	Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. <i>Radiation Oncology</i> , 2018, 13, 167.	2.7	14
11	Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. <i>Transfusion</i> , 2012, 52, 542-548.	1.6	12
12	A Rare Case of Primary High-Grade Large B-Cell Lymphoma of the Sciatic Nerve. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e117-e120.	0.4	12
13	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 165.e1-165.e11.	1.2	11
14	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
15	Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 72-6.	0.5	9
16	Nodular pulmonary amyloidosis: a complex disease with malignancy association. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220428.	0.5	8
17	Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. <i>Cancer Genetics</i> , 2020, 240, 40-44.	0.4	8
18	Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>Advances in Radiation Oncology</i> , 2021, 6, 100714.	1.2	6

#	ARTICLE	IF	CITATIONS
19	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	6
20	Association Between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing. <i>JAMA Dermatology</i> , 2020, 156, 817.	4.1	5
21	Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 645-652.	1.7	5
22	BRAF p.V600E associated poly-neoplastic syndrome. <i>Rare Tumors</i> , 2021, 13, 203636132110129.	0.6	4
23	Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 1037-1043.	1.7	4
24	T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma. <i>Rare Tumors</i> , 2015, 7, 160-162.	0.6	3
25	Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation. <i>Leukemia Research Reports</i> , 2020, 13, 100197.	0.4	3
26	Intranodal Sirolimus Induces Regulatory T Cells in Human Hepatic Lymph Nodes via Interleukin 10 Signaling. <i>Liver Transplantation</i> , 2021, 27, 1669-1672.	2.4	3
27	Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2022, Volume 12, 23-29.	2.7	3
28	Disseminated extranodal marginal zone lymphoma involving the gastrocnemius muscle with sural neurolymphomatosis. <i>Annals of Hematology</i> , 2015, 94, 1939-1940.	1.8	2
29	A case of ampullary follicular lymphoma. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 731-732.	1.0	2
30	Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.4	2
31	Plamotamab (XmAb[®] 13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 738-742.	1.3	2
32	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.4	2
33	Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 47-54.	2.7	2
34	A case of exuberant cutaneous lymphomagenesis in the setting of chronic patch mycosis fungoides. <i>JAAD Case Reports</i> , 2015, 1, 46-48.	0.8	1
35	Systemic ALKâ€positive anaplastic large cell lymphoma with bilateral optic neurolymphomatosis resulting in permanent blindness. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2629-2633.	0.5	1
36	Primary ageâ€related EBVâ€associated effusionâ€based lymphoma successfully treated with rituximab and thoracentesis. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e03971.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 67-72.	2.7	1
38	Low-Dose Methotrexate Causing Fatal Pancytopenia in a Patient With Severe Malnutrition. <i>Journal of Clinical Rheumatology</i> , 2020, Publish Ahead of Print, .	0.9	1
39	B Cell Acute Lymphocytic Leukemia Presenting as a Bile Duct Stricture Diagnosed With Cholangioscopy. <i>ACG Case Reports Journal</i> , 2016, 3, e107.	0.4	1
40	Unique Clinical Epidemiologic Risk Factors Are Associated with Distinct Methylation Subgroups in Newly-Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 1719-1719.	1.4	1
41	Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy. <i>Journal of Blood Medicine</i> , 2021, Volume 12, 833-838.	1.7	0
42	Primary peritoneal myeloid sarcoma in association with CFBF/MYH11 fusion. <i>Leukemia Research Reports</i> , 2021, 15, 100238.	0.4	0
43	Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype. <i>Blood</i> , 2019, 134, 5210-5210.	1.4	0
44	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588.	1.4	0
45	Utilization and Cost Effectiveness of First-Line Yttrium-90 Ibritumomab Tiuxetan in Low-Grade Follicular and Marginal Zone Lymphomas Compared to Standard of Care Bendamustine Plus Rituximab: A Real-World Experience. <i>Blood</i> , 2021, 138, 4020-4020.	1.4	0
46	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). <i>Blood</i> , 2021, 138, 3437-3437.	1.4	0
47	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	1.4	0
48	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2285-2285.	1.4	0
49	CD68+ Tumor Associated Macrophages Have Significant Impact on Therapeutic Outcome in Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 4-5.	1.4	0
50	Molecular Epidemiology of AML: Association of Somatic Gene Mutations with Epidemiologic Exposures and Outcomes in the Mayo Clinic AML Epidemiology Cohort. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
51	A 71-Year-Old Man With Diffuse Waxing and Waning Multifocal Lung Lesions, Empyema, and Episodic Fevers Reveals a Rare Diagnosis. <i>Chest</i> , 2022, 161, e35-e41.	0.8	0
52	Polarization of Macrophages in Granulomatous Cutaneous T Cell Lymphoma Granulomatous Mycosis Fungoides Microenvironment. <i>Dermatopathology (Basel, Switzerland)</i> , 2022, 9, 54-59.	1.5	0